Share About the API
Ixazomib citrate is used for treating multiple myeloma in its finished dose formulation. Its mechanism of action involves functioning as a proteasome inhibitor, disrupting the normal function of proteasomes in cells.
At Teva api we offer Ixazomib Citrate API Form II, which is the same as the brand. In addition, our own proprietary process leverages our expertise to handle boronates, resulting in a high-quality API. GMP material is now available, and full validation will be completed in March 2024.
Ixazomib Citrate API is currently developed and produced for R&D purposes and regulatory submissions only.
About the API
-
Japan DMF
-
Korea DMF
-
US DMF
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.
